Bayer AG (BAY) Completes Transaction Involving Plasma Business; Announcing The Launch Of Talecris Biotherapeutics, Holdings Corp.: Combining A Proud History Of Patient Care With A Bold New Vision
10/19/2005 5:13:11 PM
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--April 1, 2005--
Talecris To Apply Innovative Approach to Its Inherited, 60-Year Legacy of Providing Life-Saving and Life Enhancing Plasma-Derived Therapeutic Proteins
Talecris Biotherapeutics, Holdings Corp. (Talecris), a new corporation that acquired the contributed assets of Bayer HealthCare, LLC, Biological Products Division's (BP) plasma business, today launches its worldwide therapeutic proteins business, Talecris Biotherapeutics, Inc.
The transaction between Bayer and Talecris was completed yesterday, with the new company becoming operational today. Private investment firms Cerberus Capital Management, L.P., New York, and Ampersand Ventures of Wellesley, Mass., provided the financial backing for Talecris.